CN106511978A - A fibronectin oral cavity histocyte regeneration liquid - Google Patents
A fibronectin oral cavity histocyte regeneration liquid Download PDFInfo
- Publication number
- CN106511978A CN106511978A CN201610991532.5A CN201610991532A CN106511978A CN 106511978 A CN106511978 A CN 106511978A CN 201610991532 A CN201610991532 A CN 201610991532A CN 106511978 A CN106511978 A CN 106511978A
- Authority
- CN
- China
- Prior art keywords
- fibronectin
- regeneration
- oral cavity
- cell
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A fibronectin oral cavity histocyte regeneration liquid is disclosed. The liquid is characterized by comprising 0.10-1.50 mg/mL of fibronectin (FN), 0.5-5% of polyethylene glycol, 3-10% of xylitol and 0.5-5% of glycine. Based on regeneration medical science principles, and by utilizing a biological characteristics that the fibronectin can promote cell proliferation and regeneration of oral cavity gland cells, oral cavity mucous membrane endothelial cells, epithelial cells, odontoblasts, and other cells, the objective of achieving oral cavity histocyte restoration and regeneration is achieved. The polyethylene glycol and the glycine are adopted as a stabilizing agent and an absorption promoter of the fibronectin. The xylitol plays a role of a stabilizer and a role of a sweetener to adjust taste.
Description
Technical field
The present invention relates to a kind of promote oral cavity gland cell, mucous membrane of mouth endothelial cell, epithelial cell, odontoblast
Deng cell proliferation regeneration, and then the regenerated liquid of Regeneration and Repair oral cavity tissue, specifically a kind of fibronectin oral tissue cell is again
Raw liquid.
Background technology
Regenerative medicine is a fast-developing field, and it is intended to the mechanism for seeking regeneration and is applied to disease or injury tissue
The therapeutic strategy that 26S Proteasome Structure and Function recovers.Regenerative medicine includes cell transplantation, the structure of bioid artificial organ（Work is organized
Journey）And the chemical induction regeneration of remnant tissue in situ.In terms of health medical treatment, due to tissue damage, human reg ability defect
And caused medical expense（Only in the U.S., estimate more than 40,000,000,000 dollars every year）With cap loss, quality of life decline,
The economic loss that premature death etc. is caused is quite huge.Regenerative medicine is as brand-new medical disciplines, not only pre-
Prevent and treat basic disease, and the 26S Proteasome Structure and Function of the histoorgan damaged because of disease and trauma will be repaired.
Injury of mouth regeneration is more and more concerned, and oral keritonocytes, periodontium are damaged, oral cavity body of gland regenerates etc.
Problems demand is solved.With the development of regenerative medicine, including cell transplantation, the structure of bioid artificial organ and remnants groups in situ
The regenerative medicine methods such as the chemical induction regeneration knitted gradually are received by clinical medicine in interior new method and technology, and are obtained
Larger achievement.For example, carrying out regeneration method to the periodontium of periodontitis destruction has periodontal bone grafting operation, guide tissue regeneration
Art, growth factor-induced, stem cell transplantation etc..
Fibronectin（Fibronectin, FN）It is a kind of macromolecule glycoprotein, is widely present in animal tissue and tissue fluid
In, with various biological function.Its wide participation cell migration, stick, breed, stopping blooding and the process such as tissue repair, transferring
Mononuclear phagocyte system removes harmful substance at injury tissue, acts on growth factor.Matrix of the FN as cell culture,
The adherent rate of various kinds of cell can be improved, converge rate, shorten the cell confluency time, make cellular prion protein good, metabolic rate strengthens,
DNA, RNA and protein aggregate velocity are significantly improved；The colony rate of cell is raised, and original cuiture survival rate is improved.In regeneration doctor
Field, in terms of the application of FN mainly has three below：
（1）FN and cell transplantation
Transplanted cells suspend or assemble depending on they break up and self be assembled into three-dimensional original structure stereochemical structure and
With the needs of the fusion of host around.This depends on damage location cell signal and adhesion molecule（FN）Appearance and adjacent healthy
The 3-D solid structure of tissue.It is understood that the tissue for carrying out maintenance regeneration is necessary for maintaining tissue reconstruction to provide necessary letter
Number.Equally, the independence regeneration of damaged tissues is also required for the signal of indispensability.Meanwhile, the environment of damaged tissues necessarily has part
Signal hinder regeneration, this be due to these tissue often start regeneration response after be fiberized suppression.
（2）FN and bioid artificial organ
The purpose of bioid artificial organ is, before which is transplanted in vivo, to be built using the support of likeness in form damaged tissues organ and closed
Suitable tissue morphology and structure substitute.Ideally, bioid artificial organ can simulate ECM functions in human body, no
Geometry and physicochemical property are only provided, enable cell to divide a word with a hyphen at the end of a line through support to greatest extent, and have the ability to integrate and release
Bio signal necessary to putting cell propagation and breaking up, fibronectin（FN）Play a significant role in this continuous process.FN
Or be individually present or combined with other ECM molecules or connective tissue matrix is become by decellularization and is widely used as bioid
The support of artificial organ or the regeneration template from host tissue induction.
（3）The induction of in-situ regeneration
The induction of regenerative medicine in-situ regeneration is exactly the behavior or operation that recognize all kinds of growth factors or small molecule and simulate them
Local injection activates their signal transduction pathway, or by having again in the induction in situ of damaged part regeneration template or the circulatory system
The cell of raw ability is regenerated.Fibronectin（FN）As the growth factor needed for " supporting regeneration " environment, in signal transduction
And there is in inducing cell regenerative process irreplaceable effect.
The content of the invention
The purpose of the present invention is exactly using above know-why, based on above-mentioned prior art situation, and according to practical application
Effect and a kind of fibronectin oral tissue cell regenerated liquid for developing, practical application research find that FN can promote oral cavity body of gland
The proliferation regenerations such as cell, mucous membrane of mouth endothelial cell, epithelial cell, odontoblast, the proliferation regeneration of these cells is mouth
The Regeneration and Repair of chamber injury tissue provides necessary requirement.
The purpose of the present invention is achieved through the following technical solutions：A kind of fibronectin oral tissue cell regeneration
Liquid.Its formula is made up of following component proportioning：
Fibronectin（FN） 0.10-1.50mg/ml
- 8000 0.5-5% of Macrogol 4000（Weight ratio）
Glycine 0.5-5%（Weight ratio）
Xylitol 3-10%（Weight ratio）
Physiological saline surplus
PH value 6.0 8.0
In the present invention, fibronectin（FN）Can promote oral cavity gland cell, mucous membrane of mouth endothelial cell, epithelial cell, into tooth
The cell proliferation regeneration such as this cell plastid, can be organized with Regeneration and Repair injury of mouth, belong to core functional component.
Polyethylene glycol, glycine in the present invention connects egg to maintaining fibronectin Stability Analysis of Structures, keeping fine as stabilizer
White biologically active has very important effect, promotes absorption of the mucous membrane of mouth to fibronectin at the same time as accelerator.This
Molecular weight polyethylene glycol scope in invention is chosen to be 4000-8000, is because the polyethylene glycol of the molecular weight ranges to human body
Have no toxic side effect, and with higher structural stability, be best suitable for maintaining fibronectin Stability Analysis of Structures, keep fibronectin biological
Activity, promotion absorption of the mucous membrane of mouth to fibronectin, the polyethylene glycol of other molecular weight ranges do not have the advantage of this respect.
Xylitol in the present invention plays a part of flavor adjustment, it is adaptable to various people（As diabetes patient and preferably suffered from dental caries
Children of tooth etc.）, the stability of fibronectin also can be protected as stabilizer.
The preparation method of fibronectin oral tissue cell regenerated liquid of the present invention is：Each raw material is weighed in component ratio,
Put in reactor after xylitol, glycine, polyethylene glycol are dissolved with normal saline dilution respectively and be heated to 120-150 degree,
Sterilizing 30-40 minutes, it is stand-by that standing is down to Room-temperature seal.By fibronectin aperture used for decontamination chamber be 1.0 μm, 0.65 μm,
0.22 μm of biological filter membrane is degerming, finally under hundred grades of purification conditions mixes various feed liquids, stirs, with 50%HCl and
40%NaOH adjusts PH to 6-8, plus sterile saline to reach intended volume, by specification and quality requirement embedding, packs, checks, goes out
Factory.
Product of the present invention can be applicable to the more health care and treatment of crowd for a long time of the low oral disease of immunocompetence.Using side
Method：Oral cavity is cleaned after the meal every time, and fibronectin oral tissue cell regenerated liquid is sprayed directly on to into oral cavity, action of gargling repeatedly,
Extend the time of staying in oral cavity as far as possible, finally slowly spue or swallow.It is daily 3-4 time, add before sleeping and use once more preferable.
Innovative point is as follows compared with prior art for the present invention：
1st, the present invention give full play to fibronectin promote oral cavity gland cell, mucous membrane of mouth endothelial cell, epithelial cell, into tooth sheet
The biological characteristics of the cell proliferation regeneration such as cell plastid, expands the application of fibronectin, to meet market user more
Extensive demand, can be applicable to the more health care and treatment of crowd for a long time of the low Buccodental illness of immunocompetence.
2nd, invention product formula combination science is suitable for, and each component is pure biological raw material, and human body is had no toxic side effect, each composition
Between mutually act synergistically, particularly polyethylene glycol, glycine are to maintaining fibronectin Stability Analysis of Structures, keeping fibronectin biological
Activity, promotion mucous membrane of mouth with important effect, are capable of achieving oral health benefits and maximize to the absorption of fibronectin.The product
Product formula has no report both at home and abroad at present.
In addition, my company development teams are in Chinese core medical journals《Preclinical medicine and clinic》In December, 2014 volume 34
Entitled " the fibronectin that 12nd phase P1655 1657 is delivered（FN）Fibronectin has been mentioned in the paper for the treatment of canker sore "
Preparation has good curative effect to treating canker sore, and in contrast, the present invention has the advantage that：（1）Mention in paper
Fibronectin preparation is composition unitary agent, and product formula of the present invention is multicomponent preparation, is had good between each composition
Coordination, facilitation, to promoting oral tissue cell regeneration with more remarkable result；（2）By oral tissue cell culture pair
Find than experiment, product formula of the present invention is to promoting the speed of cell growth, propagation than the fibronectin preparation mentioned in paper
Fast 1.5 times；Found by clinical practice contrast, product formula of the present invention is discussed to the efficient and cure rate ratio for treating canker sore
Mention in text fibronectin preparation difference it is high by 12.1%, 9.8%, to treat gingivitis efficient and cure rate than carrying in paper
Arrive fibronectin preparation difference it is high by 15.8%, 11.3%.It is indicated above that product formula of the present invention is than the fine even egg mentioned in paper
White preparation has more preferable in terms of promoting oral tissue cell regeneration, treatment canker sore, repairing oral mucosa damage and anti-inflammatory
Curative effect.
3rd, compared with my another patent of invention of company " edible type fibronectin chewing gum ", patent of the present invention with
Lower innovative point：Patented product formula Jing of the present invention is verified repeatedly and is got, to promoting oral cavity gland cell, mucous membrane of mouth endothelium thin
The cell proliferation regeneration such as born of the same parents, epithelial cell, odontoblast has effect well, and " edible type fibronectin mouth is fragrant
The formula of sugar " only to treating the mouth diseases such as canker sore, periodontitis, pulpitis in terms of there is curative effect, promoting cell propagation
Good result is not shown in terms of regeneration.Found by oral tissue cell culture contrast experiment, product formula pair of the present invention
Promote the formula of cell growth, the speed ratio " edible type fibronectin chewing gum " of propagation fast 1.7 times.
4th, production technology simplicity specification of the present invention, strong applicability, are capable of achieving industrially scalable metaplasia and produce.Core functional component
The production of fibronectin raw material is our patented technology, and the fibronectin oral liquid that we research and develop is achieved with authenticating authority machine
The security credential of structure Switzerland SGS, including the security credential such as heavy metal physical and chemical index, microbiological indicator, all kinds of indexs are complete
It is complete qualified.Other auxiliary materials are market convenient source, so exploitation this product is capable of achieving good economic benefit and social benefit.
5th, this product using method is simple and convenient, and Jing is on probation very popular with users, with the market demand potential.
Specific embodiment
The present invention is described further below in conjunction with example：
Example 1：
100 milliliters of fibronectin oral tissue cell regenerated liquids are prepared, each component can be weighed by following consumption：Fibronectin：
0.06g, polyethylene glycol：1g, xylitol：5g, glycine：1g.
Preparation method is：Each raw material is weighed in component ratio, first, Macrogol 4000, glycine, xylitol is mixed
Close, vessel in heating are put into 130 DEG C with 50 milliliters of physiological saline solutions, be incubated sealing in 30 minutes, stand and be down to room temperature and put only
Change room stand-by for raw material A.With 30 milliliters of physiological saline by fibronectin via hole diameter be 1.0 μm, 0.65 μm of biofilm filtration, hundred
It is degerming stand-by for raw material B with 0.22 μm of biomembrane in level clean bench, finally under ten thousand grades of purification conditions in hundred grades of clean benches
Raw material A and raw material B are mixed, is adjusted PH to be 7.0, plus the physiological saline of sterilizing is stirred, by specification and quality to 100 milliliters
Require embedding, packaging.
Example 2：
100 milliliters of fibronectin oral tissue cell regenerated liquids are prepared, each component can be weighed by following consumption：Fibronectin：
0.15g, polyethylene glycol：5g, xylitol：10g, glycine：5g.
Preparation method is：Each raw material is weighed in component ratio, first, Macrogol 4000, glycine, xylitol is mixed
Close, vessel in heating are put into 130 DEG C with 50 milliliters of physiological saline solutions, be incubated sealing in 30 minutes, stand and be down to room temperature and put only
Change room stand-by for raw material A.With 30 milliliters of physiological saline by fibronectin via hole diameter be 1.0 μm, 0.65 μm of biofilm filtration, hundred
It is degerming stand-by for raw material B with 0.22 μm of biomembrane in level clean bench, finally under ten thousand grades of purification conditions in hundred grades of clean benches
Raw material A and raw material B are mixed, is adjusted PH to be 7.0, plus the physiological saline of sterilizing is stirred, by specification and quality to 100 milliliters
Require embedding, packaging.
Example 3：
100 milliliters of fibronectin oral tissue cell regenerated liquids are prepared, each component can be weighed by following consumption：Fibronectin：
0.01g, polyethylene glycol：0.5g, xylitol：3g, glycine：0.5g.
Preparation method is：Each raw material is weighed in component ratio, first, Macrogol 4000, glycine, xylitol is mixed
Close, vessel in heating are put into 130 DEG C with 50 milliliters of physiological saline solutions, be incubated sealing in 30 minutes, stand and be down to room temperature and put only
Change room stand-by for raw material A.With 30 milliliters of physiological saline by fibronectin via hole diameter be 1.0 μm, 0.65 μm of biofilm filtration, hundred
It is degerming stand-by for raw material B with 0.22 μm of biomembrane in level clean bench, finally under ten thousand grades of purification conditions in hundred grades of clean benches
Raw material A and raw material B are mixed, is adjusted PH to be 7.0, plus the physiological saline of sterilizing is stirred, by specification and quality to 100 milliliters
Require embedding, packaging.
Claims (3)
1. a kind of fibronectin oral tissue cell regenerated liquid, it is characterised in that：It is made up of following component proportioning：
Fibronectin（FN） 0.10-1.50mg/ml
Polyethylene glycol 0.5-5%
Glycine 0.5-5%
Xylitol 3-10%
Surplus physiological saline.
2. fibronectin oral tissue cell regenerated liquid according to claim 1, it is characterised in that：The polyethylene glycol
Molecular weight is 4000-8000.
3. fibronectin oral tissue cell regenerated liquid according to claim 1, it is characterised in that：The fibronectin mouth
The pH value 6.0 8.0 of cavity tissue cytothesis liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610991532.5A CN106511978A (en) | 2016-11-11 | 2016-11-11 | A fibronectin oral cavity histocyte regeneration liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610991532.5A CN106511978A (en) | 2016-11-11 | 2016-11-11 | A fibronectin oral cavity histocyte regeneration liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511978A true CN106511978A (en) | 2017-03-22 |
Family
ID=58351033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610991532.5A Pending CN106511978A (en) | 2016-11-11 | 2016-11-11 | A fibronectin oral cavity histocyte regeneration liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511978A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312744A (en) * | 2017-06-18 | 2017-11-03 | 广东博溪生物科技有限公司 | A kind of Buccal mucosa cell nutrient solution containing serum |
| CN110664651A (en) * | 2019-11-16 | 2020-01-10 | 许帅辉 | Composition for treating oral mucosa repair and preparation method thereof |
| CN113499428A (en) * | 2021-06-25 | 2021-10-15 | 上海淳誉健康科技有限公司 | Cell engineering transdermal nutrition-based fibronectin anti-aging regeneration repair method |
| CN113576980A (en) * | 2021-08-31 | 2021-11-02 | 广东丸美生物技术股份有限公司 | Composition with ulcer repairing effect and application thereof |
| CN113577378A (en) * | 2021-08-28 | 2021-11-02 | 上海纤瑞生物技术有限公司 | Fibronectin liquid wound spray dressing and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816534A (en) * | 2014-03-25 | 2014-05-28 | 王斌 | Fibronectin (FN) oral agent for preventing and curing gastric and intestinal ulcers |
| CN103875880A (en) * | 2014-03-25 | 2014-06-25 | 王斌 | Edible fibronectin chewing gum |
| CN105214071A (en) * | 2015-05-28 | 2016-01-06 | 上海昊海生物科技股份有限公司 | A kind of size variance eye drop and preparation method thereof |
-
2016
- 2016-11-11 CN CN201610991532.5A patent/CN106511978A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816534A (en) * | 2014-03-25 | 2014-05-28 | 王斌 | Fibronectin (FN) oral agent for preventing and curing gastric and intestinal ulcers |
| CN103875880A (en) * | 2014-03-25 | 2014-06-25 | 王斌 | Edible fibronectin chewing gum |
| CN105214071A (en) * | 2015-05-28 | 2016-01-06 | 上海昊海生物科技股份有限公司 | A kind of size variance eye drop and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 李捷玮等: "《常用药物辅料手册》", 30 June 2000, 第二军医大学出版社 * |
| 王斌等: "纤连蛋白（FN）治疗口腔溃疡", 《基础医学与临床》 * |
| 薛大权: "《聚乙二醇在医药学领域的应用与技术》", 30 April 2011, 华中科技大学出版社 * |
| 陈兰英: "《首都医院制剂汇编》", 31 August 1982, 人民卫生出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312744A (en) * | 2017-06-18 | 2017-11-03 | 广东博溪生物科技有限公司 | A kind of Buccal mucosa cell nutrient solution containing serum |
| CN107312744B (en) * | 2017-06-18 | 2020-09-25 | 广东博溪生物科技有限公司 | Serum-containing oral mucosa epithelial cell culture solution |
| CN110664651A (en) * | 2019-11-16 | 2020-01-10 | 许帅辉 | Composition for treating oral mucosa repair and preparation method thereof |
| CN113499428A (en) * | 2021-06-25 | 2021-10-15 | 上海淳誉健康科技有限公司 | Cell engineering transdermal nutrition-based fibronectin anti-aging regeneration repair method |
| CN113577378A (en) * | 2021-08-28 | 2021-11-02 | 上海纤瑞生物技术有限公司 | Fibronectin liquid wound spray dressing and preparation method and application thereof |
| CN113576980A (en) * | 2021-08-31 | 2021-11-02 | 广东丸美生物技术股份有限公司 | Composition with ulcer repairing effect and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106511978A (en) | A fibronectin oral cavity histocyte regeneration liquid | |
| Mozzati et al. | The impact of plasma rich in growth factors on clinical and biological factors involved in healing processes after third molar extraction | |
| CN104906126B (en) | For treating the composition of cartilage disease | |
| CN104822381B (en) | Therapeutic combination and method | |
| CN102630157B (en) | Injectable compositions for intra-articular use combining a viscosupplementation agent and a fibroblast growth medium | |
| CN106902381A (en) | Recombination human source collagen stoste, dressing and their preparation method | |
| EP0742022A4 (en) | Biologically compatible hydrogel | |
| WO2008072371A1 (en) | Preparation for sterilization or disinfection of tissue | |
| Wang et al. | Horizon of exosome-mediated bone tissue regeneration: the all-rounder role in biomaterial engineering | |
| US20120177619A1 (en) | Composition comprising a haematic component and its use for the treatment of degenerative joint disease | |
| Gani et al. | Effectiveness of Combination of Chitosan Gel and Hydroxyapatite from Crabs Shells (Portunus pelagicus) Waste as Bonegraft on Periodontal Network Regeneration through IL‐1 and BMP‐2 Analysis | |
| Bosco et al. | A histologic and histometric assessment of the influence of nicotine on alveolar bone loss in rats | |
| CN105412986B (en) | Small intestinal submucosa carries piece and its preparation method and application of building up one's health by taking tonic | |
| CN101584889B (en) | External in-situ forming matrix used for treating periodontal diseases | |
| CN108339122A (en) | A kind of preparation method and application of antiallergic bioactivity glass powder | |
| DE60223707T2 (en) | CALCIUM-L-THREONATE FOR THE TREATMENT OF BONE FRACTURES | |
| Karmakar et al. | Attributes of Nanomaterials and Nanotopographies for Improved Bone Tissue Engineering and Regeneration | |
| CN105288739B (en) | A kind of guided periodontal tissue regeneration biomembrane and its preparation method and application | |
| Arpita et al. | Recent trends in non-surgical periodontal care for the general dentist-a review | |
| Dan et al. | Synergistic approach of graphene oxide-silver-titanium nanocomposite film in oral and dental studies: A new paradigm of infection control in dentistry | |
| JPWO2005025605A1 (en) | Therapeutic agents and methods for periodontal and pulpal diseases | |
| Klama‐Baryła et al. | The use of biostatic human amnion and platelet‐rich plasma in topical treatment of toxic epidermal necrolysis—a case report | |
| CN205235020U (en) | Icariin - small intestine submucosa patch | |
| Wang et al. | Applications of hydrogels in tissue-engineered repairing of temporomandibular joint diseases | |
| Messer et al. | Attachment of human epithelial cells and periodontal ligament fibroblasts to tooth dentin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |